ANN ARBOR, Mich., Feb. 4, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that George W. Dunbar, President and Chief Executive Officer, will present at the 11th Annual BIO CEO & Investor Conference. The conference will be held February 9-10th at the Waldorf-Astoria Hotel in New York City, NY. Mr. Dunbar will present at 9:30 a.m. (Eastern Time), on Monday, February 9, 2009.

A live webcast of Aastrom's presentation can be accessed by logging onto the web at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=ASTM&item_id=2079677. A replay of the presentation will be archived for 90 days, at the same site.

For more information, please visit the conference website at: http://www.ceo.bio.org/opencms/ceo/2009/.

The Aastrom Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3663

About Aastrom Biosciences, Inc.

Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC) technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC technology platform has positioned Aastrom to advance multiple products into clinical development. Ongoing development activities are focused on applying TRC technology to cardiac and vascular tissue regeneration. The company is currently focused on cardiovascular regeneration and is conducting a Phase II clinical trial with dilated cardiomyopathy (DCM) patients (the IMPACT-DCM trial) and a Phase IIb clinical trial with critical limb ischemia (CLI) patients (the RESTORE-CLI trial).

This document contains forward-looking statements, including, without limitation, statements concerning clinical trial strategies, potential partnering activities, product development objectives, potential advantages of TRC technology and TRC-based products, and potential product applications, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "intends," "expect," "expected," "should," "anticipated," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are clinical trial results, potential product development difficulties, the effects of competitive therapies, regulatory approval requirements, the availability of financial and other resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

CONTACT:  Aastrom Biosciences, Inc.
          Investor Relations
          Kris M. Maly
          Kimberli O'Meara
          (734) 930-5777

          Cameron & Associates 
          Investors
          Kevin McGrath
          (212) 245-4577

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.